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ABSTRACT 
Motivation: Hepatocellular carcinoma (HCC) is the fifth most common type of liver cancer and the second most frequent 
cause of cancer‐related death worldwide [1]. The recommended first‐line treatment for patients with locally advanced disease 
and well-preserved liver function is Sorafenib with a mean overall survival of 11 months [2]. Other drugs have been developed 
to increase the therapeutic arsenal of treatments such as Lenvatinib [3], Regorafenib [4]  and Cabozantinib [5]. The Bcl-2 
protein family plays a central part in the control of apoptosis [6]. Bcl-2, Bcl-XL and Mcl-1 are antiapoptotic members Bax, Bak, 
Bid, and Bim are proapoptotic members. The cytoprotective function of Bcl-2 proteins stems from their ability to antagonize 
Bax and Bak, and thus prevent apoptosis. [7]. The aim of the present study was the comparative analysis of the tyrosine 
kinase inhibitors in cell death and proliferation, and the expression of Bcl-2 family members according to the differentiation 
degrees and p53 genetic profile in liver cancer cells. 
Methods: Sorafenib, Regorafenib, Cabozantinib, and Lenvatinib were obtained commercially from Carbosynth Limited. 
Parameters were assessed in differentiated cells: HepG2 (ATCC/LGC Standards, SLU, Barcelona, Spain) and Huh7 (Apath 
LLC, Brooklyn, USA), and dedifferentiated cells: JHH2 and JHH4 cell lines obtained from the Japanese Collection of Research 
Bioresources Cell Bank (Tokyo, Japan). Cells were negative for mycoplasma contamination. HCC cell lines were maintained in 
supplemented Minimum Essential Medium with Earle's Balanced Salts at 37°C in a humidified incubator with 5 % CO2. Cells 
were seeded at a density of 10^5 cells/cm2 in 2D culture. Different parameters related to cell death and proliferation were 
associated with the expression of Bcl-2 family members assessed by Western-blot analysis. 
Results: The administration of tyrosine kinase inhibitors induced cell death and reduced cell proliferation. This effect was 
associated with an upregulation of tBid and Bim expression in differentiated liver cancer cells (HepG2 and Huh7) compared to 
dedifferentiated cells (JHH2 and JHH4, respectively). In addition, the lack of p53 in liver cancer cells (Huh7 and JHH4) had a 
lower degree in the expression compared to their p53 wild type counterpart (HepG2 and JHH). 
Conclusions: The dedifferentiation of cancer cells and mutated p53 reduce the upregulaupregulation of Bim and Bid induced 
by Sorafenib and Regorafenib in liver cancer cells. 
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